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MEETING REPORT
Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and
perspectives, March 31 – April 1, 2016, Tours, France
Guillaume Desoubeauxa,b,c,*, Janice M. Reichertd,e, Matthew Sleemanf, Karen L. Reckampg, Bernhard Ryffelh,i,
J€org P. Adamczewskij, Theresa D. Sweeneyk, Rita Vanbeverl, Patrice Diota,b,c, Caroline A. Owenm,n, Clive Pageo,
Stephanie Lerondelp, Alain Le Papea,b,p, and Nathalie Heuze-Vourc’ha,b,*
aUniversite Franc¸ois-Rabelais, Tours, France; bINSERM, Center d’Etude des Pathologies Respiratoires, Tours, France; cCentre Hospitalo-Universitaire de
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Cambridge, UK; gCity of Hope, Comprehensive Cancer Center, Duarte, CA, US; hUniversite d’Orleans, Orleans, France; iUniversity of Cape Town, Institute
of Infectious Disease and Molecular Medicine (IDM), Cape Town, South Africa; jSanoﬁ R&D, Chilly-Mazarin, France; kNektar Therapeutics, San Francisco
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Pharmacology, London, UK; pPHENOMIN-TAAM CNRS, CIPA, Orleans, France
ABSTRACT
Monoclonal antibody (mAb) therapeutics have tremendous potential to beneﬁt patients with lung
diseases, for which there remains substantial unmet medical need. To capture the current state of mAb
research and development in the area of respiratory diseases, the Research Center of Respiratory Diseases
(CEPR-INSERM U1100), the Laboratory of Excellence “MAbImprove,” the GDR 3260 “Antibodies and
therapeutic targeting,” and the Grant Research program ARD2020 “Biotherapeutics” invited speakers from
industry, academic and government organizations to present their recent research results at the
Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current challenges and perspectives congress
held March 31 – April 1, 2016 in Tours, France.
Abbreviations: [18F]FES, 16a-[18F]Fluoro-17b-estradiol; ADC, antibody-drug conjugate; ADCC, antibody-dependent
cell-mediated cytotoxicity; AhR, aryl hydrocarbon receptor; BAFF, B-cell activating factor; BAL, bronchial-alveolar
lavages; CARD9, caspase activation and recruitment domains 9; CCL16, Club cell protein-16; CDC, complement-
dependant cytotoxicity; CODV, cross-over dual variable; COPD, chronic obstructive pulmonary disease; CS, cigarette
smoke; CT, computed tomography; CTLA-4, cytotoxic T lymphocyte-associated antigen 4; Da, Dalton; DVD, dual-var-
iable-domain; EGFR, epidermal growth factor receptor; EPR, enhanced permeability and retention; ER, estrogen
receptor; FcRn, neonatal Fc receptor; HER2, human epidermal growth factor receptor 2; Hrsv, human respiratory
syncytial virus; HRV, human rhinovirus; IL, interleukin; IPF, idiopathic pulmonary ﬁbrosis; IV, intravenous; kDa, Kilo-
daltons; LDH, lactate dehydrogenase; mAb, monoclonal antibody; MMP-9, matrix metalloproteinase-9; MRI, mag-
netic resonance imaging; NHP, non-human primate; NIRF, near-infrared ﬂuorescence; NLRP3, pyrin domain
containing 3; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PEG, polyethyl-
ene glycol; PD, pharmacodynamics; PD-1, programmed death 1; PD-L1, PD-1 ligand; PET, positron emission tomog-
raphy; PFS, progression-free survival; PK, pharmacokinetics; PMN, polymorphonuclear leucocytes; RSV, respiratory
syncytial virus; scFv, single-chain variable fragment; SCID, severe combined immunodeﬁciency; SPECT, radioisotopic
single photon emission CT; ST2, interleukin 1 receptor-like 1; TBTi, tetravalent bispeciﬁc tandem immunoglobulin;
Th, T-helper; TNFa, tumor necrosis factor a; TMARD, Monoclonal Antibodies for Respiratory Diseases: Current chal-
lenges and perspectives; UK, United Kingdom; US, United States of America; VEGF, vascular endothelial growth
factor
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On March 31, 2016, the meeting Monoclonal Antibodies for
Respiratory Diseases (TMARD, http://tmard.sciencesconf.
org/): Current challenges and perspectives was opened by Herve
Watier (Co-Director of LabEx MAbImprove), Nathalie
Heuze-Vourc’h (President of TMARD scientiﬁc committee),
Patrice Diot (Dean of Tours School of Medicine) and Pierre
Commandeur (Vice-president of Center-Val de Loire region),
who welcomed participants and thanked the organizers and
both institutional and industrial sponsors.
The ﬁrst speaker, Janice M. Reichert (The Antibody Society;
Reichert Biotechnology Consulting LLC), discussed monoclonal
antibody (mAb) therapeutics in development for respiratory
disorders, as well as neurological, infectious, cardiovascular /
hemostasis diseases.1 While antibody therapeutics for cancer
and common immune-mediated disorders, e.g., rheumatoid
arthritis, psoriasis, Crohn’s disease, are discussed frequently,
development of mAbs for these other therapeutic areas are not
often the focus of attention. To provide context, Dr. Reichert
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noted that global antibody therapeutics research and develop-
ment by the biopharmaceutical industry has undergone remark-
able expansion in the past»5 years. Resulting from a substantial
dedication of effort and resources, over 100 novel antibodies
entered ﬁrst clinical studies in 2015, and the overall clinical pipe-
line now includes »480 antibodies. Importantly for patients,
these molecules are progressing through the phases of clinical
testing, and being approved for marketing. To date, over 50 anti-
body therapeutics for a variety of diseases are in Phase 3 studies.1
A record number, i.e., 9 new products, were granted ﬁrst mar-
keting approvals in the United States or European Union in
2015, and the evidence suggests that a similar number may be
approved in 2016. As examples, Dr. Reichert provided details
for obiltoxaximab, ixekizumab and reslizumab, 3 mAb products
already approved by the Food and Drug Administration in
2016. Obiltoxaximab (Anthim), targeting the protective anti-
gen of Bacillus anthracis exotoxin, is indicated in adult and pedi-
atric patients for treatment of inhalational anthrax due to
Bacillus anthracis in combination with appropriate antibacterial
drugs, and for prophylaxis of inhalational anthrax when alterna-
tive therapies are not available or appropriate. Ixekizumab
(Taltz), targeting interleukin IL17A, is indicated for treatment
of adults with moderate-to-severe plaque psoriasis, whereas
reslizumab (Cinqair), targeting IL5, is indicated for severe
asthma in adults.
Dr. Reichert then focused on antibodies developed for respi-
ratory, neurological, infectious or cardiovascular / hemostasis
diseases, which, excluding cancer and common immune-medi-
ated disorders, are the therapeutic areas that include the most
mAbs in development. Neurological disorders represent the
largest area (27 mAbs; 11 in Phase 2/3 or Phase 3 studies), fol-
lowed by cardiovascular / hemostasis (25 mAbs; 6 in Phase 3
studies), infectious disease (24 mAbs; 3 in Phase 3 studies) and
respiratory disease (22 mAbs, 4 in Phase 3 studies). Most
(»90%) mAbs in development for these therapeutic areas are
canonical IgG1, IgG2, IgG4 or IgM that may have been Fc- or
glyco-engineered. In contrast, relatively few, i.e., less than
20 mAbs, have non-canonical formats, e.g., bispeciﬁc, antibody
fragments (domain, nanobody, single-chain variable fragment
(scFv), Fab). In the respiratory disorder area, Dr. Reichert
discussed 4 mAbs that are undergoing evaluation in Phase 3
studies for asthmatic patients: anti-IL5 receptor benralizumab,
anti-IL4 receptor a dupilumab, anti-IL13 lebrikizumab, and
anti-IL13 tralokinumab. Benralizumab is also undergoing eval-
uation in Phase 3 studies of patients with chronic obstructive
pulmonary disease (COPD). Thus, Dr. Reichert noted that this
latter is an “antibody to watch” in 2016, because its results for 4
Phase 3 studies of asthma patients are expected in 2016, and, if
they are positive, marketing application submissions may occur
later in the year.
In concluding her talk, Dr. Reichert emphasized that the
recent increase in the number of mAbs in clinical studies is
expected to drive a trend toward ﬁrst approvals for »6–8 new
mAbs per year (or more), including mAbs for respiratory disor-
ders. She cautioned that the sustainability of this trend depends
on the veriﬁcation of expected increases in potency of engi-
neered antibodies and bispeciﬁc antibodies, and the validity of
the novel targets for mAbs in development. However, if the
recent past reﬂects the near future, unmet medical need should
be reduced and patient choices for antibody therapeutics
should increase in the next »8 years, which is the average time
for mAb clinical development.
Session 1: Anti-infectious monoclonal antibodies
Matthew Sleeman (MedImmune) opened the session dedicated
to anti-infectious mAbs with a talk entitled ‘Targeting Patho-
gens’. Increasingly, mAbs targeting different cytokines, includ-
ing IL13 and IL5, are being considered as therapeutic options
for the treatment of severe respiratory conditions such as
asthma, idiopathic pulmonary ﬁbrosis (IPF) and COPD. While
many of these anti-cytokine approaches demonstrated promise,
the majority of hospitalizations in these diseases are caused by
common pathogens triggering exacerbations of their condi-
tions. Therefore, therapies directly targeting pathogens may
provide signiﬁcant beneﬁt. He showed ﬁrst that, due to anti-
genic diversity, direct targeting of pathogens has been challeng-
ing and requires a detailed understanding of the stable proteins
on a pathogen surface that can be accessed by mAbs. One such
example is the antibody palivizumab (Synagis), which binds
to the key target fusion-protein of respiratory syncytial virus
(RSV). It has been approved for the prevention of infections in
premature infants. In addition to this, anti-RSV vaccines have
been generated that, if successful, could provide longer term
protection for at risk individuals. MAb therapies, such as palivi-
zumab, are unfortunately the exception rather than the rule in
the prevention or treatment of infectious disease. Thereafter,
Dr. Sleeman discussed an alternative approach, which is the
design of antibodies to the host co-receptor to prevent viral
entry and infection. To illustrate his talk, he presented the
human rhinovirus (HRV), which is responsible for the com-
mon cold and virally-driven respiratory exacerbations in
asthma and COPD. HRV is made up of 3 distinct clades: HRV-
A, HRV-B and HRV-C consisting of greater than 167 distinct
serotypes. With such diversity, the ability to design a mAb that
would neutralize all serotypes is extremely challenging; a differ-
ent option could be to target one of the co-receptors: intercellu-
lar adhesion molecule 1 (ICAM-1), low-density lipoprotein
receptor (LDLR) or cadherin-related family member 3
(CDHR3). Using mouse models of HRV infection, Dr. Sleeman
showed that ICAM-1 was elevated on the bronchial epithelium
of the lung, and that an ICAM1 neutralizing antibody (14C11)
could prevent HRV driven lung inﬂammation, viral infection
and cytokine production whether the antibody was adminis-
tered directly to the airways or was given systemically.2 In addi-
tion, he also showed published data that soluble-ICAM1 given
to healthy human volunteers pre-inoculation with HRV signiﬁ-
cantly reduced daily symptoms scores compared with placebo.3
While these data support the hypothesis of using the co-recep-
tors as a target to prevent viral infections, signiﬁcant questions
remain, especially in the context of a respiratory exacerbations,
such as which viral serotypes triggers the exacerbations, could
non-HRV viruses, bacteria or fungal pathogens be the cause of
some exacerbations or would one need to target all 3 co-recep-
tors for maximal impact? Finally, Dr. Sleeman considered tar-
geting the downstream pro-inﬂammatory molecules produced
as a consequence of pathogen invasion in the lungs. One of
these key targets gaining substantial interest is the cytokine
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IL33, which is highly expressed in the epithelium of the lung
and rapidly released upon lung infection with, for example,
inﬂuenza-A, RSV or HRV. Using a mouse model of COPD, he
also went on to show that chronic cigarette smoke (CS) expo-
sure caused an accumulation of IL33 in the epithelium, and
that this was rapidly released following an inﬂuenza infection,
causing chronic inﬂammation.4 Furthermore, he showed that
this response was signiﬁcantly blunted in mice deﬁcient in
either IL33 or interleukin 1 receptor-like 1 (ST2). The associa-
tion with this cytokine and respiratory exacerbations has also
been shown in samples from severe asthmatics.5 In conclusion,
targeting respiratory pathogens with mAbs is a distinct possi-
bility and has been clearly demonstrated with molecules such
as palivizumab; however, signiﬁcant but not insurmountable
challenges remain. Firstly, isolating neutralizing antibodies to
many pathogens is complex and challenging; secondly, target-
ing co-receptors is a distinct possibility, but there could be sig-
niﬁcant redundancy where a pathogen may use different or
multiple co-receptors; or thirdly targeting downstream path-
ways of infection could provide beneﬁt, but may require a per-
sonalized healthcare approach to identify the key pathways that
predominate in any one individual.
Thomas Secher (INSERM U1220-IRSD) presented results
on panobacumab, a human IgM against Pseudomonas aerugi-
nosa serotype O11 lipopolysaccharides.6-8 Panobacumab is able
to reduce P. aeruginosa burden in lungs by enhancing neutro-
phil recruitment and reducing the host-derived production of
pro-inﬂammatory mediators, and thereby reduces lung injury
in a murine model of lung infection, whatever the immune sta-
tus. Regarding its additional effects when given in association
with meropenem, panobacumab may be combined with stan-
dard antibiotic therapy. These encouraging preclinical data
have been recently conﬁrmed in a short-scale Phase 2 clinical
trial in which the full treatment of panobacumab was shown to
induce a complete resolution in patients presenting with noso-
comial P. aeruginosa pneumonia compared to untreated
individuals.9
Session 2: Anti-cancer monoclonal antibodies
Karen L. Reckamp (City of Hope Comprehensive Cancer Cen-
ter) started the second session of the congress by reminding
attendees how clinical trials using mAbs in lung cancer have
recently improved patient outcomes. She began her talk with a
discussion of the anti-vascular endothelial growth factor
(VEGF) bevacizumab (Avastin), which was approved for
treatment of non-small cell lung cancer (NSCLC) a decade
ago.10 The initial Phase 3 trial, which compared carboplatin
and paclitaxel with and without bevacizumab in patients with
advanced NSCLC with non-squamous histology, demonstrated
a statistically signiﬁcant improvement in objective response
rate (ORR) and progression-free survival (PFS) with the addi-
tion of bevacizumab. It was also the ﬁrst study to report a
median overall survival (OS) greater than 12 months in such a
population. A subsequent 3-arm Phase 3 trial investigated cis-
platin and gemcitabine with placebo or bevacizumab at 2 dose
levels in patients with similar NSCLC;11 patients assigned to
the bevacizumab arms had statistically superior ORR and PFS.
Dr. Reckamp then showed results of the Phase 3 trial in
which docetaxel with placebo or ramucirumab (Cyramza), a
mAb against the extra-cellular domain of VEGF-receptor 2,
was administered to patients who had experienced disease pro-
gression after platinum-based therapy.12 Statistically signiﬁcant
higher ORR, longer PFS and longer OS were observed with
ramucirumab. In all, predictive biomarkers for anti-angiogene-
sis antibodies have not been identiﬁed. Afterwards, Dr.
Reckamp reported the multiple clinical trials that have evalu-
ated anti-epidermal growth factor receptor (EGFR) mAbs in
combination with chemotherapy to enhance the efﬁcacy of
cytotoxic therapy. For instance, a Phase 3 trial investigated cis-
platin and gemcitabine with and without necitumumab
(Portrazza), a mAb against the extra-cellular domain of the
EGFR in patients with advanced NSCLC with squamous histol-
ogy.13 Those who received necitumumab had a similar response
rate, but a statistically signiﬁcant longer PFS and OS, while a
similar trial in patients with advanced non-squamous NSCLC
failed to demonstrate improved efﬁcacy.14
Thereafter, Dr. Reckamp showed how anti-programmed
death 1 (PD-1) mAbs, like nivolumab (Opdivo), have
improved survival as monotherapy for patients with NSCLC
as second-line therapy compared to docetaxel.15-17 A Phase 3
study of nivolumab versus docetaxel in squamous cell histol-
ogy showed an improvement in OS of 9.2 months vs.
6 months, respectively. Nonetheless, in these subjects, PD-1
ligand (PD-L1) expression did not appear to be prognostic
or predictive of patient outcome at any level. In addition, the
Phase 3 trial in patients with previously treated non-squa-
mous histology showed that median OS was signiﬁcantly
improved at 12.2 months for nivolumab and 9.4 months for
docetaxel. In contrast with the previous trial, in this study
PD-L1 expression was predictive of clinical beneﬁt, although
the OS was also similar in both arms when PD-L1 was not
expressed. Then, Dr. Reckamp provided details on pembroli-
zumab (Keytruda), a highly selective humanized IgG4-
kappa mAb against PD-1: a single arm trial enrolled 495
NSCLC patients and correlated PD-L1 expression with
response to treatment.18 In a Phase 2/3 randomized trial
assessing pembrolizumab compared to docetaxel in patients
with previously treated advanced NSCLC who were PD-L1
positive, the median OS was signiﬁcantly longer for both
doses of pembrolizumab.17 The OS was substantially longer
in those who had at least 50% PD-L1 expression in tumor
cells. Atezolizumab is another mAb that prevents the binding
of PD-L1 to PD-1 and CD80, in addition to preserving the
interaction between PD-L2 and PD-1. It demonstrated efﬁ-
cacy when compared to docetaxel in NSCLC in a random-
ized Phase 2 study.19 To note, activation of the immune
system to produce antitumor responses leads to distinct tox-
icities related to immune stimulation. Dr. Reckamp under-
lined the numerous immune-related adverse events in
clinical trials and practice, which are greater with cytotoxic
T lymphocyte-associated antigen 4 (CTLA-4) inhibition
compared to anti-PD-1 and anti-PD-L1 agents, although all
these mAbs may result in life-threatening toxicities. She
concluded that antibody-based therapy for lung cancer is
well-established, and new treatments with antibodies have
demonstrated improved efﬁcacy, conﬁrming the success of
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this modality. Antibody-drug conjugates (ADC) are emerg-
ing agents in clinical trials that may lead to new therapeutic
options in the future.
Rita De Santis (Sigma Tau SpA) drew the attention of the
audience with her talk about AvidinOX –conjugated biotiny-
lated-antibody to treat cancer. AvidinOX is an oxidized version
of avidin that forms Schiff’s bases with tissue proteins, thus
constituting an artiﬁcial stable receptor for biotinylated thera-
peutics.20 Biotinylated anti-cetuximab and anti-panitumumab
antibodies, which both target EGFR, showed anti-tumor efﬁ-
cacy at a dose lower than 1/25,000 the intravenous (IV) effec-
tive dose, when delivered after AvidinOX through the airways,
in an experimental model of lung cancer in severe combined
immunodeﬁciency (SCID) mice. She explained the effect was
due to the inability of EGFR to dimerize, and subsequent inhi-
bition of signaling.21 She also emphasized the excellent tolera-
bility of AvidinOX in animals. Dr. De Santis concluded that
AvidinOX offers a great opportunity to treat lung tumors using
aerosol delivery.
Session 3: Monoclonal antibodies in asthma
Opening the third session, Bernhard Ryffel (INEM - UMR7355;
CNRS) reviewed clinical asthma and recent progress with thera-
peutic antibodies for severe and steroid resistant asthma,
highlighting bi- and multi-speciﬁc antibodies. Novel mecha-
nisms of allergic asthma focusing on Th2 and Th17 polarized
immune responses were discussed, together with recent discov-
eries that pyrin domain containing 3 (NLRP3) may act as a Th2
transcription factor enhancing Th2 dependent asthma in
mice.22 By contrast, the NLRP3 inﬂammasome complex is
required for IL1/IL17-dependent asthma.23 The IL1 family cyto-
kine IL33 is involved in the Th2 response, since antibody neu-
tralization reduces asthma, while the NLRP3 inﬂammasome is a
negative regulator dampening allergic asthma.24 In addition,
RORgc-dependent production of IL17A/F and IL22 by ILC3
and T-cells drives severe neutrophilic asthma, representing
additional novel therapeutic targets. With the present insights of
the interplay of microbiota, nutrition, infection and the immune
response, new preventive/therapeutic options are likely to
emerge. Selected food, probiotics, recombinant bacilli, and
microbial metabolites such as short chain fatty acids may have
anti-inﬂammatory effects and could be used as complementary
prevention or therapy. Reduced production of tryptophan
metabolites by microbiota from caspase activation and recruit-
ment domains 9 (CARD9)-deﬁcient mice and patients with
Crohn’s disease diminish aryl hydrocarbon receptor (AhR) acti-
vation and increase inﬂammation.25 Therefore, the administra-
tion of AhR agonists inducing an AhR-dependent protective
IL22 response may be beneﬁcial in asthma. Dr. Ryffel also
underlined the use of germfree and mono-colonization with
protective bacterial species, which may provide new insights on
the protective effect of Clostridia controlling inﬂammatory Bac-
teriodetes species. However, investigation by bacterial depletion
with antibiotics is problematic due to selection of resistant
strains.
Dr. Ryffel then reminded the attendees that environmental
factors, including air pollution, chemicals, tobacco smoke,
ozone and respiratory infections, are other factors inﬂuencing
the allergic respiratory responses. Experimental studies in mice
exposed to ozone develop severe, neutrophilic, steroid resistant
airway hyper-reactivity and inﬂammation representing a major
therapeutic challenge. Preliminary data using ozone exposure
suggest that this type of severe asthma is sensitive to M3 mus-
carinic antagonists, but IL17 targeting might also be consid-
ered.26 In addition to classical immune mediators, the targeting
of neural reﬂexes, central nervous system mediators/neuropep-
tides could represent another exciting and promising approach.
The preclinical investigation of novel human targeted therapeu-
tics is required prior to use in patients. Human mAbs, but also
single chain antibodies, dominant negative inhibitors, nanoﬁ-
tines, fusion proteins and lipocalins27 targeting speciﬁc human
proteins may be tested in non-human primates, if there is sufﬁ-
cient cross-reactivity. The recent development of humanized
immune system mice and human knock-in mice, in which
mouse protein is replaced by the human analog of, for example,
tumor necrosis factor (TNF), CD20, CD64, B-cell activating
factor (BAFF), or neonatal Fc receptor (FcRn), are available
and may be helpful. These novel humanized mice will enable in
vivo investigations of efﬁcacy, pharmacokinetics and, impor-
tantly, novel routes of administration such as inhalation. In
conclusion, Dr. Ryffel added that basic research leading to new
therapeutics that neutralize key-mediators is emerging, which
may improve the control of allergic asthma and reduce steroids.
Harshad P. Patil (Universite Catholique de Louvain) began
his talk by reminding attendees of the deleterious role of IL17
in asthma. He showed the beneﬁt of an anti-IL17 Fab’ antibody
associated with high molecular-weight polyethylene glycol
(PEG, 20–40 KDa) and delivered locally into the lungs
to achieve local targeted activity against inﬂammation. The
PEGylated anti-IL17 Fab’ substantially reduced neutrophils
recruitment, lactate dehydrogenase (LDH) and TNF in bron-
chial-alveolar lavages (BAL) of asthmatic mice. Moreover,
weekly pulmonary delivery of 20 mg PEGylated anti-IL17 Fab’
was as effective as 10 times-higher doses of non-PEGylated
anti-IL17 Fab’ given by subcutaneous route. Dr Patil also
revealed that PEGylation prolonged residency of anti-IL17 Fab’
in the luminal side of the lungs, through different mechanisms
like enhanced proteolytic resistance, attachment to the mucus
and escape from alveolar macrophages.28 These ﬁndings are
promising for the future development of anti-asthma strategies.
Session 4: Antibody format
Opening session 4, J€org P. Adamczewski (Sanoﬁ R&D) gave an
overview on bi- and multi-speciﬁc antibodies from a drug
developer’s perspective. He raised 2 key questions that were
discussed on the basis of current examples from multiple thera-
peutic areas: 1) how to exploit the biological effects of a
multi-speciﬁc antibody to achieve a therapeutic effect, and 2)
what antibody format to choose for a desired outcome. Bispe-
ciﬁc antibodies have 2 biological effects: they bind to 2 targets
simultaneously and bring them into spatial proximity. There-
fore, which of these mechanisms is exploited to achieve the
desired therapeutic effect deﬁnes the 2 basic classes of such
antibodies. However, even if the spatial action is not the aim, it
needs to be considered as a potential source of undesired bio-
logical outcomes, especially if neither target is a soluble protein.
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Dr. Adamczewski reminded attendees that multi-targeting anti-
bodies typically block 2 or more receptors or ligands to inhibit
parallel pathways leading to converging biological or patho-
physiological processes. However, they can also be used to tar-
get an escape pathway at the same time as the principal target,
or to achieve deep inhibition by blocking the same pathway at
2 points. As speciﬁc example, SAR156597 is a tetravalent bispe-
ciﬁc antibody that targets the 2 Th2 cytokines IL4 and IL13.
Both cytokines have been implicated in pathophysiology of
IPF, a progressive ﬁbrotic disease of the lungs in which 3 key
cell types play a possible role in the disease pathogenesis, airway
epithelial cells, lung ﬁbroblasts and lung macrophages, making
them an attractive target for parallel pathway blockage. He
pointed out that SAR156597 is currently the only multi-speciﬁc
antibody in clinical development for non-infectious respiratory
disease, with a Phase 2 proof-of-concept trial in IPF (clinical-
trials.gov/ct2/show/NCT02345070) ongoing.
Dr. Adamczewski then highlighted the interest in using bis-
peciﬁc antibodies to bring 2 targets into physical proximity.
Spatial use is the most common approach for anti-cancer
immune cell engagers, in which the antibody activates an
immune effector cell, typically a cytotoxic T-cell targeted on
CD3, and homes it to a surface antigen on a tumor cell, result-
ing in cell death. The approval of blinatumomab (Blincyto),
targeting both CD3 and the B-lineage antigen CD19, for
relapsed/refractory acute lymphoblastic leukemia demonstrated
the power of such T-cell engagers.29 An equivalent approach
can be used to force the association of 2 proteins, as illustrated
by emicizumab, which induces binding of factor IXa to factor X
in the absence of sufﬁcient factor VIII, thus restoring blood
coagulation. A Phase 3 trial in hemophilia A patients is ongoing
(clinicaltrials.gov/ct2/show/NCT02622321). The speaker
explained that optimization for different biological properties,
but also parallel historical developments, led to over 50 bispe-
ciﬁc formats, allowing ﬁne-tuning for the desired biological
effect, e.g., pharmacokinetics (PK), including tissue penetration,
antibody-dependent cell-mediated cytotoxicity (ADCC), com-
plement-dependant cytotoxicity (CDC). Stable symmetric,
IgG-like formats such as the dual-variable-domain (DVD) for-
mat class or tetravalent bispeciﬁc tandem immunoglobulin
(TBTi) including SAR156597, combine longer PK, the option
of effector functions and greater ease of process development
over smaller constructs based on antibody fragments, which
may have superior tissue penetration. Dr. Adamczewski
indicated that Sanoﬁ’s third-generation crossover dual variable
Ig-like proteins (CODV) bispeciﬁc format allows greater versa-
tility and maintains full binding speciﬁcity of both parental
antibody sequences.30 He concluded that multi-speciﬁc
antibodies are thus a versatile tool to achieve powerful thera-
peutic effects that currently seems underutilized in respiratory
diseases, and may provide additional opportunities for patient
beneﬁt in the future.
Next, Jean-Franc¸ois Gestin (Inserm U892 – CNRS 6299)
gave an overview of the radiolabelled companion diagnostic
tests that he introduced as non-invasive “imaging biopsy-like”
tools. For instance, he explained that radiolabelled vector 16a-
[18F]Fluoro-17b-estradiol ([18F]FES) has proven to be a valu-
able tracer for the studies of the estrogen receptor (ER) status
of primary and metastatic breast cancer. Dr. Gestin then
focused on other impressive examples related to radiolabelled
companion diagnostic tests, like anti-human epidermal growth
factor receptor 2 (HER2) antibody (89Zr-trastuzumab or 64Cu-
DOTA-trastuzumab) to determine the HER2 status in primary
breast tumor, but also PK and accessibility to adapt the treat-
ment in case of relapse and metastasis.31,32 He concluded that
radiolabeled companion diagnostics, like radiolabeled mAbs,
are supporting tools to aid therapeutic decisions, ensuring
effective selection of patient eligible for treatment and giving
individuals more effective and safer treatments. They may be of
interest for lung cancer patients.
Session 5: Inhaled antibodies
Theresa Sweeney (Nektar Therapeutics) opened the session
focused on use of the pulmonary route to deliver mAbs for
respiratory diseases. She noted that mAb therapy is well
accepted for the treatment of cancer and auto-immune disease,
but few mAbs are approved for the treatment of respiratory dis-
ease and none are delivered by the pulmonary route. In theory,
inhalation delivery offers the advantage over intravenous deliv-
ery of a high dose delivered directly to the target organ, i.e.,
lungs, while limiting system exposure and potential side effects.
Yet until recently, the delivery efﬁciency of inhalation devices
and the added cost of therapy have limited the development of
inhaled biologics for pulmonary disease. Dr. Sweeney reviewed
the history of inhaled mAbs delivery by describing the experi-
ence with anti-IgE (omalizumab, Xolair) for the treatment of
asthma. She described the rationale for inhalation delivery of
anti-IgE and the data that supported the targeting of lung IgE
over systemic IgE.33 Anti-IgE was not successful in ameliorat-
ing the broncho-constrictive response in mild asthmatics when
delivered by inhalation despite a high lung dose,34 suggesting
that both lung and systemic IgE neutralization was required for
efﬁcacy. Full-length mAbs have low bioavailability,35 and
smaller forms could offer advantages because they may better
penetrate tissues to reach target receptors. Dr. Sweeney sug-
gested that recent advances in the pathogenesis of asthma and
COPD may provide better understanding of therapeutic targets,
and that the development of new technologies may offer
improvements over full-length mAbs. Lower molecular weight
and more potent forms of antibodies are being evaluated for
topical delivery, including an anti-IL13 Fab for the treatment of
asthma36 and a highly potent nanobodyTM to treat RSV infec-
tion.37 Dr. Sweeney concluded that improved knowledge of
therapeutic targets, antibody fragments, potent molecules, and
more efﬁcient delivery systems are important for the success of
inhalation delivery for the treatment of pulmonary disease.
Next, Rita Vanbever (Universite catholique de Louvain)
unraveled the fate of pulmonary-delivered mAbs. She noted
that a major drawback of inhalation is the short residence time
of antibodies in the lungs as they are mostly cleared from the
lungs within one to 2 d.28,35 In contrast, plasma half-lives of
full-length antibodies after injection reach 3 weeks and more.38
Accordingly, most antibodies developed for the treatment of
respiratory diseases are delivered by injection,39 except for an
inhaled single-domain antibody (Nanobody

) speciﬁc for RSV
fusion protein. Because injection presents limitations, including
high delivered doses, low antibody penetration in the lungs and
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potential systemic side effects, she explained that inhalation of
antibody therapeutics deserves further investigation. Based on
that, Dr. Vanbever presented her results on antibody formats
that would allow the longest retention within the lungs. Com-
pared with full-length antibodies, engineered antibody frag-
ments present advantages, such as enhanced tissue penetration,
binding to cryptic epitopes, multi-speciﬁc actions and econom-
ical production in bacteria.40 A F(ab’)2 and a Fab’ antibody
fragments were shown to be as quickly cleared from the lungs
as a full-length antibody.28 Therefore, full-length antibodies do
not provide any apparent lung pharmacokinetic advantage
over these antibody fragments. Interestingly, she showed that
conjugation of antibody fragments to one large molecular
weight PEG chain sustained the residence time of the proteins
within the lungs.28 High levels of PEGylated antibody frag-
ments persisted in the lungs for more than 2 d post-delivery.
All antibody constructs were principally located within the air-
way lumen rather than the lung parenchyma. In addition, PEG
increased pulmonary retention of antibody fragments through
muco-adhesion and escape from alveolar macrophages, rather
than by increased hydrodynamic size or improved enzymatic
stability. The deeper the deposition site of the antibody con-
structs within the lungs, the longer the molecules were retained.
A two-armed 40 kDa PEG better prolonged residence time than
a linear 20 kDa PEG, although the effect of PEG molecular
weight was slight. Dr. Vanbever concluded by showing that the
increased pulmonary residency of antibody fragments through
PEGylation was conﬁrmed in 3 small animal species.
Finally, Renaud Respaud (CEPR-INSERM U1100) showed
evidence to support that delivery of full-length mAbs through
the airways is feasible and relevant in the treatment of respira-
tory diseases.35,41-43 When they are delivered through the pul-
monary route, mAbs achieved a therapeutic response, in some
experimental conditions, greater than when they were delivered
systemically. Although the fate of mAbs within the lungs
remained unclear after airway delivery, they passed slowly and
poorly into the systemic circulation. Dr. Respaud also
highlighted the importance of mAb stability during aerosoliza-
tion, and showed that mesh nebulizers prevented better mAbs
degradation and concentration. Addition of surfactant was crit-
ical to maintain mAb molecular integrity and pharmacological
activity during vibrating-mesh nebulization.
Concluding remarks
Patrice Diot (Dean of Tours School of Medicine; CEPR-
INSERM U1100) concluded the ﬁrst day of the TMARD
symposium by reiterating the basics and challenges related to
respiratory medicine. He started by summarizing the challenges
in medicine, from the beginning of its history to the current
times, i.e., 1) to take into account the epidemiology of the dis-
eases, and to establish priorities to set up public health pro-
grams; 2) to understand their pathophysiology, which has
eventually allowed over time to simplify the concepts and to
make bridges between various types of disorders; 3) to establish
the accurate diagnosis; 4) to prescribe the efﬁcient treatment;
and 5) eventually to establish and communicate the prognosis,
at the level of individuals and of communities. He underlined
that respiratory medicine is special because it mainly concerns
diseases which, in terms of epidemiology, are at the 2 extremes,
either very frequent, or on the opposite very rare or even
orphan, and which, in terms of treatment, can often not be
cured nowadays. As examples of frequent, severe and non-cur-
able respiratory diseases worldwide, COPD is projected to be
the third leading cause of death by 2020, while lung cancer is
currently the ﬁrst cause of death by cancer, and 16% of children
are suffering from asthma. In contrast, cystic ﬁbrosis and IPF
seem rarer, extremely severe, and non-curable diseases.
In terms of their pathophysiology, Pr. Diot said that: “respi-
ratory diseases, as diseases of any other system in fact, are very
simple, as they basically correspond to genetic, infectious,
inﬂammatory or cancer disorders.” He pointed out that the
concept of the accuracy of a treatment, in medicine in general,
is a mixture of its efﬁciency, side effects, convenience, and
price. There have been several periods in the history of medi-
cine with regards to the development of therapeutics: the chem-
ical period, with for example the major advances represented by
the discovery of aspirin, penicillin, or streptomycin; then the
robotic advent which allowed major advances in surgery; and
thereafter the digital period. More recently, personalized thera-
pies, like those based on mAbs, have arisen, especially in respi-
ratory diseases. Pr. Diot concluded that several challenges with
regards to the proliferation of mAbs in therapeutics, e.g., the
target(s), the physico-chemical characteristics, the route of
administration, the safety and the price, and acknowledged that
all these aspects have been addressed during the various ses-
sions of the symposium.
Session 6: Animal models in respiratory diseases
On the second day, Caroline Owen (Brigham and Women’s
Hospital; Harvard Medical School) started by outlining the
healthcare burden associated with COPD. She pointed out that,
despite over 50 y of research on COPD, we still lack any dis-
ease-modifying medical therapies. She described animal models
of COPD that have been used to test hypotheses on pathogene-
sis or the efﬁcacy of novel therapies for this disease: the current
gold standard model for COPD is to expose mice to CS for
6 months.44 Dr. Owen described the advantages of CS-exposed
mice as a model system, including the fact that: 1) they develop
some features of the human disease (pulmonary inﬂammation,
small airway ﬁbrosis and airspace enlargement);44 2) their
genome can be manipulated to delete or over-express single
genes; 3) they breed rapidly; 4) they are relatively inexpensive
to house and study; and 5) tools to study their pathways are
generally commercially-available. Dr. Owen then enumerated
some disadvantages of CS-exposed mice as a model system for
COPD, including the major differences in the anatomy and
immunology between humans and mice, the fact that mice
develop minimal COPD-like airway disease, they do not
develop mucus hyper-secretion like in chronic bronchitis, and
the fact that longitudinal blood and lung sampling is challeng-
ing or not feasible in mice. Dr. Owen also highlighted that ther-
apies that had efﬁcacy in limiting the progression of COPD-like
lung disease in CS-exposed mice were subsequently shown not
to have efﬁcacy in limiting disease progression in human
COPD patients in randomized clinical trials.45,46
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Dr. Owen then discussed the anatomical and immunologi-
cal relevance of non-human primates (NHP), and thus how
they could have potential as a new animal model of COPD.
Thus, she went on to describe a novel NHP larger animal
model of COPD-like airway disease that she and her col-
leagues have recently characterized.47 After presenting the
methodology, she showed that NHPs exposed to CS for
12 weeks did not lose weight, but developed robust COPD-
like airway disease, including airway epithelial mucus cell
metaplasia, submucosal gland hypertrophy and hyperplasia,
had higher airway leukocyte counts, i.e., macrophages, poly-
morphonuclear (PMN) leucocytes, and lymphocytes, small
airway ﬁbrosis, increases in peri-bronchial lymphoid aggre-
gates, and robust reductions in airway Club cell protein-16
(CCL16) immunostaining similar to that occurring in human
COPD airways.48 Although CS-exposed NHPs did not develop
emphysema or increases in lung compliance by 12 weeks, they
exhibited changes that contribute to emphysema development
including increases in: 1) BAL ﬂuid levels of matrix metallo-
proteinase-9 (MMP-9), interleukin-8 and CCL2; 2) alveolar
macrophage MMP-12 levels; 3) parenchymal macrophage,
PMN, and lymphoid aggregate counts; 4) lung oxidative stress
levels; and 5) alveolar septal cell apoptosis. CS-exposed NHPs
also had a strong trend toward reduction in forced expiratory
volume in 0.1 second, which may reﬂect the small airway dis-
ease that develops after 12 weeks of CS exposure.47 Dr. Owen
concluded that CS-exposed NHPs have considerable potential
as a model of airway disease phenotypes occurring in COPD
patients, especially chronic bronchitis and small airway ﬁbro-
sis. Unlike mice, NHPs can safely undergo longitudinal sam-
pling in both blood and lung compartments, which could be
useful for validating novel biomarkers for COPD, and per-
forming PK and pharmacodynamics (PD) studies of novel
therapeutics for COPD-like airway disease.
Next, Frederic Ducancel (iMETI; DRF; CEA; U1184;
IDMIT) presented the IDMIT facility for “Infectious Disease
Models and Innovative Therapies” (IDMIT, http://www.idmit
center.fr) dedicated to preclinical studies using NHP models.
He emphasized that these latter are under development in the
ﬁeld of respiratory medicine to test different prophylactic and/
or therapeutic candidates for human inﬂuenza, whooping-
cough, tuberculosis and anthrax. For instance, a model of ﬂu
infection is being carried out in collaboration with the Baylor
Institute for Immunology Research and Tulane University to
study vaccine proteins engineered to speciﬁcally target skin and
mucosal dendritic cells. The goals are to characterize the early
molecular and cellular mechanisms at the skin level following
vaccination by in vivo imaging to evaluate immune-induced to
vaccine-candidates, and to compare/establish the protective
efﬁcacy of vaccine versus challenging with various ﬂu virus
strains.
Session 7: Relevance of animal models
Clive Page (King’s College of London) gave an engaging lec-
ture, picking up on Pr. Diot’s points and enlightening attend-
ees on the strengths and limitations of animal models to
support drug development for respiratory diseases and predict
translation to humans. First, he mentioned that the mouse is
increasingly being utilized as a model to investigate the patho-
genesis of asthma and COPD, and to help in the search for
novel treatments. However, there is growing concern about
how predictable murine models are in selecting new treat-
ments because there has been a catalog of failures of potential
new drugs based on work in the mouse. He explained that a
major problem is that much of our understanding of allergic
asthma has heavily relied on allergic models in the mouse but
there is very little consistency between laboratories concerning
the protocols used for sensitization and challenge. The superﬁ-
cial attractiveness of the mouse is the availability of tools and
reagents, particularly to investigate the immunological basis of
allergic inﬂammation. However, as stated before by Caroline
Owen through the example of COPD, the lung physiology of
the mouse is quite different to that of man, and due to their
size they are not the most convenient species to reliably mea-
sure lung function, particularly using the same animal as its
own control to investigate longitudinal changes in lung func-
tion or bronchial responsiveness. Furthermore, most models
of allergic asthma have been acute and have evaluated drugs
on allergen-induced eosinophilia rather than evaluating
chronic changes or measurements of lung function.
Pr. Page then underlined that one of the major phenotypic
characteristic of asthma is bronchial hyperresponsiveness,
which is not normalized by current therapies, even following
treatment with glucocorticosteroids for a decade.49 This sug-
gests that mechanisms other than airways inﬂammation con-
tribute to this phenomenon.50 Accordingly, animal models that
allow longitudinal measurement of lung function in the same
animal investigated chronically are required to understand this
process in more details. Furthermore, such a model must
exhibit the spectrum of airway responsiveness to both direct
and indirect acting provocation stimuli as seen in patients with
clinical asthma.51 Then, Pr. Page showed how his group used
rabbits and guinea-pigs, rather than just relying on mice, over
several decades to investigate the mechanisms of bronchial
hyperresponsiveness.52-54 He ﬁrst pointed the value of the rab-
bit in this context as it is of a size that allows minimally invasive
lung function recordings to be made in the same animals over
time.52,53 More recently, Pr. Page’s group used the guinea pig to
aid in the development of a novel class of inhaled bifunctional
drug for the treatment of asthma and COPD, the dual phos-
phodiesterase (PDE) 3/4 inhibitor RPL554,55 where animal
studies predicted the clinical efﬁcacy of this drug in man.
RPL554 is now in Phase 2b clinical trials.56 He concluded on
the importance of choosing the right species for drug develop-
ment, in particular for mAbs.
Next, Stephanie Blanc (Cynbiose) presented a cynomolgus
macaque model of mild infection with human RSV (hRSV),57,58
a common respiratory infection in premature infants and chil-
dren, associated with a high mortality when developing with
other chronic diseases. She showed that age and repeated infec-
tions affected virological, clinical and immunological parame-
ters. Even in infant macaques, intranasal hRSV infection
induced both local and systemic immune responses to efﬁ-
ciently control the virus. Then, Dr. Blanc illustrated that this
model was pharmacologically validated using a reference topi-
cal treatment in humans based on palivizumab (Synagis)
administered intranasally, allowing a signiﬁcant reduction in
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virus replication. Overall, this model of hRSV is relevant, and
therefore, may be used for the testing of new therapies against
RSV and different routes of administration.
Antoine Guillon (CEPR-INSERM U1100) described a novel
method to determine lung PK. First, he reminded the audience
that PK studies are required to characterize the kinetics of tis-
sue/ﬂuid deposition, transformation and clearance of an
inhaled drug for pulmonary disease. Classically, PK parameters
are estimated by monitoring drug concentrations in the sys-
temic circulation, then computed in mathematical compart-
mental models to predict the behavior of both local and
systemically acting drugs. Dr. Guillon emphasized that mAbs
do not diffuse passively into organ/tissue compartments; thus,
indirect estimation of lung concentrations by modeling from
plasma drug proﬁles is limited and sometimes biased. He pro-
vided details on a new method to quantify the time-course
exposure of inhaled mAb by direct sampling in the lung paren-
chyma, using lung microdialysis. Lung microdialysis was
already established and validated, but not for large mole-
cules.59,60 In vitro, the recovery of mAbs with a 1,000 KDa cut-
off semi-permeable membrane allowed 34% drug recovery and
sampling rate every 180 min with a ﬂow rate of 0.3 mL/min. In
vivo, lung microdialysis was set up in NHPs, a relevant animal
model for both biotherapeutics and aerosols therapy to attempt
the dynamic quantiﬁcation of mAbs in the interstitial lung
space. He explained that a microdialysis probe was implanted
in the lung by thoracic surgery immediately after delivery of
mAb aerosol in conscious NHPs, and animals were thereafter
maintained under prolonged anesthesia and mechanical venti-
lation for at least 55 hours. Microdialysate and blood samples
were collected at time intervals for the determination of mAbs
and endogenous/control markers to control the permeability of
the probe and determine in vivo mAb recovery. He concluded
that the conditions are now established for lung microdialysis
of inhaled mAbs targeting soluble-antigens, although this tech-
nique remains challenging.
Invited lecture on imaging modalities in animals to
explore the lungs
To complete the “animal models” sessions, Alain Le Pape and
Stephanie Lerondel (Center for Small Animal Imaging, Pheno-
min-TAAM CNRS) gave an overview of imaging technology to
explore the lungs. They described the imaging modalities avail-
able for lung exploration: X-ray computed tomography (CT),
radioisotopic single photon emission CT (SPECT) or positron
emission tomography (PET) imaging and magnetic resonance
imaging (MRI), which directly result from medical imaging.
Thanks to technological advances, the detectors had been
improved for both resolution and sensitivity, making it possible
to use these devices in rats and mice to perform lung explora-
tions with sub-millimetric resolution. During the last decade,
development of optical approaches such as bioluminescence
and near-infrared ﬂuorescence (NIRF) imaging have revolu-
tionized the use of molecular imaging in mice for upstream
translational research. Imaging can provide anatomical or func-
tional information, sometimes at a molecular level, that can be
combined by multimodality approaches. Pr. Le Pape and Dr.
Lerondel discussed the opportunities and applications for lung
in vivo imaging, from mice to primates and men, giving exam-
ples from lung cancer, asthma, emphysema and illustrating
aerosol-based therapies delivery. They highlighted the advan-
tages and limitations of the different techniques depending on
their physical basis and the size of the specimen submitted to
examination. In particular, they provided details on: 1) the
requirement for synchronization of images during acquisition
to prevent blurring in imaging at millimetric resolution due to
respiratory movements; 2) the dosimetry delivered to the tumor
for CT and nuclear bimodalities SPECT/CT and PET/CT for
onco-pharmacology studies in mice models to avoid bias; 3)
the limitations for accurate quantitative imaging in biolumines-
cence when the tumor becomes hypoxic; and 4) the potential of
NIRF imaging with a variety of probes to explore biomarkers
for cancer, inﬂammation and infection.
Drs. Le Pape and Lerondel also described the advanced imaging
strategies to assess interaction of mAbs or bioactive molecules with
their targets. First, they explained that direct quantitation of the
amount of a conjugated molecules concentrated into a lesion is not
an accurate quantitation of the speciﬁc recognition/interaction
because the expanded space of diffusion associated with inﬂamma-
tion, compartments inside the lesion and its environment,
enhanced permeability and retention (EPR) effect, Fc interactions
with mAbs and many other parameters may contribute to non-
speciﬁc uptake. Quantitation of interaction requires that imaging
data be corrected using those obtained with a representative but
non-activemolecule, likemutant protein or isotypemAb for exam-
ple. They also presented some results of high resolution CT and
Krypton 81m ventilation scintigraphy imaging in animal models of
asthma and emphysema. They went on to explain the rationale for
the choice of the imaging modalities (tomoscintigraphy vs. NIRF
imaging) as illustrated with a biodistribution study of cetuximab in
a mouse model of lung cancer. Finally, the potential of imaging for
translational research was illustrated with aerosolized therapies, e.
g., cetuximab or gemcitabine in lung cancer, papillomavirus vac-
cine, which provided key information on efﬁcacy, biodistribution
and safety assessments inmice, rats, primates and humans.
Conclusion
Up to 2015, a limited number of mAbs for respiratory disease
were in the market, but several molecules were recently
approved and numerous are in late phase development. This
demonstrates the potential of mAbs to beneﬁt patients with
respiratory diseases that still represent unmet medical need.
This meeting aimed at giving an overview of the molecules
approved or in development for major respiratory diseases, dis-
cussing the format and route of administration to improve efﬁ-
cacy and safety of those drugs. As mentioned by Pr. Diot, one
should keep in mind that the accuracy of a treatment is a subtle
balance between its efﬁciency, side effects, convenience, and
price. Major respiratory diseases are still non-curable, with
drugs addressing mainly the symptoms or limiting disease pro-
gression rather than reversing it. This symposium also raised
concerns regarding relevant animal models for preclinical stud-
ies. Although animal models are critical in the development of
mAbs, the choice of the species depends on the scientiﬁc ques-
tion to be addressed, and the model that might mimic human
disease best.
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